Notice Number: NOT-DA-06-026

Key Dates
Release Date: September 15, 2006

Issued by
National Institute on Drug Abuse (NIDA), (http://www.nida.nih.gov)

The National Institute on Drug Abuse (NIDA) intends to issue a Request for Applications (RFA), Development of Immunotherapeutic Products for the Treatment of Methamphetamine Addiction, in the fall of 2006. The objective of this solicitation is to support research in the design, synthesis, and pre-clinical evaluation of vaccines developed from methamphetamine-protein conjugates (heretofore referred to as methamphetamine conjugate vaccines or MCVs) for the active immunotherapeutic treatment of methamphetamine addiction. This initiative is intended to support activities focused on the development of promising MCVs as clinical candidates and to provide sufficient data required for the submission of an Investigational New Drug (IND) application to the Food and Drug Administration in support of early clinical evaluation of the new MCVs.  Mechanistic studies or clinical trials will not be supported. A multidisciplinary approach is encouraged.  Because of the complex process involved in medication development, NIDA encourages the collaboration between researchers from different disciplines and/or with industry.  Partnerships between academic or non-profit research organizations and industry are strongly encouraged, but not required. 

Inquiry

Dr. Nora Chiang 
National Institute on Drug Abuse
6001 Executive Boulevard, Room 4123
Bethesda, MD 20892 -9551
Phone:  301-443-8099
Fax:  301-443-2599
E-mail:  nchiang@mail.nih.gov

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.